Stoke Therapeutics (STOK) Current Assets (2018 - 2026)

Stoke Therapeutics' Current Assets history runs 9 years deep, the most recent figure standing at $366.7 million for Q1 2026.

• In Q1 2026, Current Assets fell 2.41% year-over-year to $366.7 million; the TTM figure through Mar 2026 stood at $366.7 million (down 2.41% YoY), while the FY2025 annual figure was $305.7 million, up 31.34% from the prior year.
• Current Assets was $366.7 million for Q1 2026 at Stoke Therapeutics, up from $305.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $375.7 million in Q1 2025 to a low of $193.3 million in Q1 2024.
• Historically, Current Assets has averaged $272.5 million across 5 years, with a median of $270.0 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Current Assets decreased 28.48% in 2024, then surged 94.4% in 2025.
• A 5-year view of Current Assets shows it stood at $244.1 million in 2022, then retreated by 11.77% to $215.3 million in 2023, then rose by 8.09% to $232.8 million in 2024, then soared by 31.34% to $305.7 million in 2025, then increased by 19.95% to $366.7 million in 2026.
• The last three Current Assets figures came in at $366.7 million (Q1 2026), $305.7 million (Q4 2025), and $272.4 million (Q3 2025), per Business Quant data.